To view a full list of publications, please see Dr. Byrne's PubMed Bibliography

Selected publications

T cell inflammation in the tumor microenvironment after neoadjuvant agonist CD40 antibody in patients with resectable pancreatic cancer
Byrne KT*, Betts CB*, Mick R*, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O’Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Clinical Cancer Research, 27(16):4574-4586, 2021.

Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
Yang F, He Z, Duan H, Zhang D, Li J, Yang H, Dorsey JF, Zou W, Nabavizadeh SA, Bagley SJ, Abdullah K, Brem S, Zhang L, Xu X, Byrne KT, Vonderheide RH, Gong Y, Fan Y. Nature Communications, 12(1):3424, 2021.

Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim SI, Cassella CR, Byrne KT. Frontiers in Immunology, 11:629722, 2021.

Agonistic CD40 monoclonal antibody APX005M and chemotherapy with or without nivolumab for the treatment of metastatic ductal pancreatic adenocarcinoma
O’Hara MH, O’Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher GA, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch L, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lacy VM, Wherry EJ, Ibrahim R, Vonderheide RH. Lancet Oncology, 22(1):118-31, 2021.

CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity
Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH. JCI Insight, 5(10):e137263, 2020.

Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
Morrison AH, Diamond MS, Hay CA, Byrne KT, Vonderheide RH. Proceedings of the National Academy of Sciences, 117(14):8022-8031, 2020.

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Hay CA, Sor R, Flower AJ, Clendenin C, Byrne KT. Journal of Visualized Experiments, (153), e60479, 2019.

Tumor cell-intrinsic factor underlie heterogeneity of immune cell infiltration and response to immunotherapy
Li J*, Byrne KT*, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ. Immunity, 49(1):178-193, 2018.

CD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne KT and Vonderheide RH. Cell Reports, 15(12):2719-32, 2016.

Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma
Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Cancer Immunology Research, 3(4):399-411, 2015.

* denotes shared first authorship
denotes shared corresponding authorship